A few weeks ago Interventional Pulmonology company Pulmonx was telling us it had a poster about its Zephyr® Endobronchial Valve (EBV) at the 18th World Congress for Bronchology and Interventional Pulmonology in Japan. Now the company has announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its Chartis Pulmonary Assessment System and Zephyr® Valve are being presented at the American Thoracic Society (ATS) International Conference, which finished on May 21st in San Diego.
The Zephyr® Endobronchial Valve is a minimally invasive device intended to treat patients with emphysema. Zephyr® EBV therapy involves bronchoscopic placement of one-way valves designed to reduce the hyperinflation characteristic of emphysema, in the diseased portion of the lungs, thereby improving the ability of the healthier portions of the lungs to function. The Zephyr® EBV is commercially available in Europe as well as other international markets and is an investigational device in the United States.
The Pulmonx Chartis Pulmonary Assessment System provides pulmonologists with lobe-specific information about a patient’s lung, enabling physicians to plan valve treatments to account for anatomical variations in the lungs of individual patients which impact the effectiveness of the valves. The addition of the Pulmonx Chartis assessment now ensures that a very high percent of treated patients will experience benefit from EBV treatment. The Chartis Pulmonary Assessment System and accessories are FDA 510(K) cleared devices.
The Chartis Pulmonary Assessment System was featured during a symposium in the presentation titled “New COPD subgroups according to prevalence and distribution of interlobar collateral ventilation assessed by an endobronchial catheter system”. This study marks the first comprehensive investigation of the presence of Collateral Ventilation (CV) by lobe in a large patient population.
The retrospective study included the analysis of 325 Chartis assessments conducted in 125 COPD patients with severe emphysema. Results indicate that approximately 70% of upper lobe predominant disease patients should have a CV- (absence of Collateral Ventilation) target for valve therapy and approximately 45% of lower lobe predominant disease patients should have a CV- target. The authors concluded that more than two-thirds of all patients had at least one CV- lung lobe and were potentially good candidates for the Zephyr EBV therapy.
“It appears that many late stage emphysema patients may be candidates for EBV therapy based on this extensive data set”, said Ralf H. Hübner, M.D., Charité University, Department of Internal Medicine, Division of Infectious Diseases and Pulmonary Medicine. “These study results reinforce what I have generally experienced in my own practice.”
Source: Pulmonx, Business Wire